Scarica l'app Stockscreener
141.20
2.37%
3.27
Dopo l'orario di chiusura:
140.36
-0.84
-0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine’s Next VMAT2 Study Adds Depth To Tardive Dyskinesia Story - Yahoo Finance
The Bull Case For Neurocrine Biosciences (NBIX) Could Change Following Its Next-Gen VMAT2 Phase 2 Trial - Yahoo Finance
Neurocrine’s New Tardive Dyskinesia Trial And What It Means For Valuation - simplywall.st
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance Australia
Will Neurocrine Biosciences Inc. stock pay special dividendsJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Mediolanum International Funds Ltd Sells 15,811 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Projected to Post Earnings on Wednesday - MarketBeat
Trading the Move, Not the Narrative: (NBIX) Edition - Stock Traders Daily
Short Interest in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Declines By 13.9% - MarketBeat
How Investors Are Reacting To Neurocrine Biosciences (NBIX) Launching Phase 2 Trial For Longer-Acting TD Drug - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 31.99% Upside Potential for Investors - DirectorsTalk Interviews
Bank of New York Mellon Corp Has $106.89 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Thrivent Financial for Lutherans Sells 215,514 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Atle Fund Management AB Has $14.41 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update - simplywall.st
Y Intercept Hong Kong Ltd Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup - Chartmill
AlphaQuest LLC Boosts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Stifel reiterates Buy rating on Neurocrine Bio stock ahead of Q4 results - Investing.com Canada
Summit Global Investments Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
21,000 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Hussman Strategic Advisors Inc. - MarketBeat
Does Neurocrine Biosciences (NBIX) Price Weakness Signal A Long Term Opportunity? - simplywall.st
Is Neurocrine Biosciences (NBIX) Offering Value After Recent Share Price Weakness - Yahoo Finance
Assessing Neurocrine Biosciences (NBIX) Valuation After New Phase 2 VMAT2 Tardive Dyskinesia Trial Launch - Yahoo Finance
Higher VMAT2 Target Occupancy Observed in Valbenazine Over Deutetrabenazine Extended-Release Capsules - NeurologyLive
Neurocrine initiates phase 2 study for tardive dyskinesia treatment By Investing.com - Investing.com Nigeria
Neurocrine Biosciences begins Phase II NBI-1065890 trial for TD - Clinical Trials Arena
Neurocrine Biosciences, Inc. (NBIX): Investor Outlook On A 31.63% Potential Upside - DirectorsTalk Interviews
Gainers Report: What is Neurocrine Biosciences Inc.’s TAM (Total Addressable Market)2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - marketscreener.com
Neurocrine initiates phase 2 study for tardive dyskinesia treatment - Investing.com
Neurocrine Biosciences, Inc. $NBIX Holdings Lifted by Wealth Enhancement Advisory Services LLC - MarketBeat
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - PR Newswire
New INGREZZA VMAT2 Data vs AUSTEDO XR Might Change The Case For Investing In Neurocrine (NBIX) - simplywall.st
Volume Report: How cyclical is Neurocrine Biosciences Incs revenue stream2025 Volume Leaders & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
(NBIX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Assessing Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Clinical Data And Pipeline Updates - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $178.00 at UBS Group - MarketBeat
What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $178 - 富途牛牛
UBS Adjusts Price Target on Neurocrine Biosciences to $178 From $188, Maintains Buy Rating - marketscreener.com
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock - Chartmill
Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? - Yahoo Finance
Recap Report: Why is Neurocrine Biosciences Inc stock going up2025 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - The AI Journal
Neurocrine sets Feb. 11 webcast for Q4 and 2025 year-end financial results - Stock Titan
Aug Analyst Calls: Is Momentus Inc Equity Warrant a momentum stockQuarterly Trade Summary & Expert Curated Trade Setups - baoquankhu1.vn
Rakuten Investment Management Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) CEO Kyle Gano Sells 36,400 Shares - MarketBeat
Seizert Capital Partners LLC Invests $9.83 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Aug Wrap: What hedge funds are buying Neurocrine Biosciences IncJuly 2025 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
8.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):